Fold the future

Sibylla is a preclinical stage company focused on developing small molecule degraders with a novel Mechanism of Action to find new therapeutics for unmet medical needs.

Our platform is powered by computer simulations and AI methods, which enables the discovery and development of compounds that induce the degradation of a target protein by interfering with its folding pathway.

By exploiting this new paradigm that we named “Pharmacological Protein Inactivation by Folding Intermediates Targeting” (PPI-FIT), Sibylla can identify and develop small molecules acting on targets involved in different types of diseases. Indeed, PPI-FIT is applicable to any therapeutic area.